TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19463378

Group type: EXPERIMENTAL
Intervention: Bivalirudin alone (n = 2,284)
Number of subjects: 7789

Group type: COMPARATOR
Intervention: Heparin plus GP IIb/IIIa inhibitor (control) (n = 2,189)
Number of subjects: 7789

Group type: EXPERIMENTAL
Intervention: Bivalirudin alone (n = 290)
Number of subjects: 7789

Group type: COMPARATOR
Intervention: Heparin plus GP IIb/IIIa inhibitor (control) (n = 317)
Number of subjects: 7789

Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 7789
Study: 16261974

Group type: EXPERIMENTAL
Intervention: BMEKL assessment system
Number of subjects: 0

Group type: COMPARATOR
Intervention: PULHEEMS assessment system
Number of subjects: 0
Study: 12113884

Group type: EXPERIMENTAL
Intervention: Soy cereal supplementation for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 10446033

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional low-fat diet
Number of subjects: 11
Study: 7884263

Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma (PRP)
Number of subjects: 191
Study: 2378982

Group type: EXPERIMENTAL
Intervention: Intensive multiagent chemotherapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: No identified Ph chromosome (control group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: POG frontline protocols for children with non‐T, non‐B‐cell ALL
Number of subjects: 58
Study: 917457

Group type: EXPERIMENTAL
Intervention: Vitamin A therapy
Number of subjects: 9
Study: 31253849

Group type: EXPERIMENTAL
Intervention: COSP intervention (n=50), 8 weekly sessions focused on coping skills
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: COSP intervention (n=50)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Attention control (n=49), 8 weekly didactic education sessions
Number of subjects: 99
Study: 31362556

Group type: EXPERIMENTAL
Intervention: Early plate fixation
Number of subjects: 178

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 178
Study: 28633819

Group type: EXPERIMENTAL
Intervention: Mono-frequency ultrasound (MFU) at 20kHz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-frequency ultrasound (DFU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tri-frequency ultrasound (TFU) at 20/35/50kHz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound pretreatment (all types)
Number of subjects: 0
Study: 25097088

Group type: EXPERIMENTAL
Intervention: Lidocaine (50 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (0.25 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lidocaine (50 mg) plus Magnesium sulfate (0.25 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 200
Study: 23051680

Group type: EXPERIMENTAL
Intervention: Home unattended portable monitoring and automatic CPAP titration
Number of subjects: 131

Group type: COMPARATOR
Intervention: Attended in-laboratory analysis
Number of subjects: 131
Study: 21743432

Group type: EXPERIMENTAL
Intervention: Experimental group (n=18) - received a 2 hour workshop on referral guidelines
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (n=19) - received customary training in oral diagnosis
Number of subjects: 37
Study: 18231111

Group type: EXPERIMENTAL
Intervention: Higher experienced continuity of care
Number of subjects: 199

Group type: COMPARATOR
Intervention: Transitions between phases of treatment
Number of subjects: 199
Study: 16595460

Group type: EXPERIMENTAL
Intervention: Vastus-splitting approach
Number of subjects: 42

Group type: COMPARATOR
Intervention: Median parapatellar approach
Number of subjects: 42
Study: 14587168

Group type: EXPERIMENTAL
Intervention: Lytic or combination therapy for patients less than 75 years of age in hospitals unable to perform early PCI.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy for patients older than 75 years unable to receive early PCI.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitated PCI in centers where PCI is readily available after discussion with the local interventional cardiology team.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy using IIb/IIIa inhibitors plus fibrinolytics and/or LMWH.
Number of subjects: 0
Study: 11040914

Group type: EXPERIMENTAL
Intervention: Diclofenac drops
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flurbiprofen drops
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 52
Study: 8790090

Group type: EXPERIMENTAL
Intervention: Oral acyclovir, 400 mg, 5 times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 50
Study: 1378138

Group type: EXPERIMENTAL
Intervention: Norepinephrine (ED50, 20-40 ng/min)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (PGF2 alpha) (ED50, 480-1,170 ng/min)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg oral administration)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 6090019

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 gm/day, administered intravenously)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cefamandole (4 gm/day, administered intravenously)
Number of subjects: 47
Study: 30878496

Group type: EXPERIMENTAL
Intervention: Robotic-assisted shoulder rehabilitation therapy (30 minutes per day, 5 times per week for 4 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 38
Study: 30541622

Group type: EXPERIMENTAL
Intervention: Pre-cognitive behavioural therapy digital 'informed choice' intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27653444

Group type: EXPERIMENTAL
Intervention: 1 mg/kg per day of azathioprine (AZA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 mg/kg per day of azathioprine (AZA)
Number of subjects: 50
Study: 25102532

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction during cystoscopy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Routine cystoscopy (Control)
Number of subjects: 45
Study: 21392837

Group type: EXPERIMENTAL
Intervention: Pharmacist directed post‐discharge home medication review (n = 64, 53.3%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (n = 56, 46.7%)
Number of subjects: 120
Study: 20194310

Group type: EXPERIMENTAL
Intervention: Cement group (Group 1)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Hybrid group (Group 2)
Number of subjects: 130
Study: 18369656

Group type: EXPERIMENTAL
Intervention: PPV with Oxane HD
Number of subjects: 20

Group type: COMPARATOR
Intervention: PPV with 1300 cs silicone oil and scleral buckle
Number of subjects: 20
Study: 16007042

Group type: EXPERIMENTAL
Intervention: Framon (0.25 mg/kg, intravenous bolus)
Number of subjects: 153
Study: 11822956

Group type: COMPARATOR
Intervention: Postoperative enteral feeding with a standard diet within 12 hours of surgery (control group; n = 50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Liquid diet enriched with arginine, omega‐3 fatty acids, and RNA for 7 consecutive days (preoperative group; n = 50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Enriched liquid diet for 7 consecutive days followed by enteral feeding with the same enriched formula (perioperative group; n = 50)
Number of subjects: 150
Study: 10365648

Group type: EXPERIMENTAL
Intervention: New cation-exchange HPLC method for plasma metformin determination
Number of subjects: 0
Study: 8964631

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) before dialysis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) at the end of treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) 6 hours after dialysis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: On line BIA during hemodialysis
Number of subjects: 12
Study: 2042756

Group type: EXPERIMENTAL
Intervention: 2% glucose in lactated Ringer's solution (D2LR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5% glucose in lactated Ringer's solution (D5LR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lactated Ringer's solution alone (LR)
Number of subjects: 45
Study: 7040528

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal aerosol (BDNA) 33.5 micrograms/burst (o.d., b.i.d., t.i.d., q.i.d.)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal aerosol (BDNA) 42 micrograms/burst (b.i.d., q.i.d.)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 30685114

Group type: EXPERIMENTAL
Intervention: Carboplatin plus Paclitaxel plus MEDI-575 (CPM)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Carboplatin plus Paclitaxel (CP)
Number of subjects: 99
Study: 28914978

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 12.5 mg/kg twice daily for EGT carrier children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 10.6 mg/kg twice daily for EGT noncarrier children
Number of subjects: 0
Study: 27102361

Group type: EXPERIMENTAL
Intervention: Curcumin (1500 mg/d BiocurcumaxTM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 24622805

Group type: EXPERIMENTAL
Intervention: Higher protein (HP) infant formula
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Lower protein (LP) infant formula
Number of subjects: 1090
Study: 22152230

Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1004
Study: 20409019

Group type: EXPERIMENTAL
Intervention: Three-quarter circumferential band configuration (PB)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Full circumferential band configuration (FB)
Number of subjects: 47
Study: 17360125

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 16275869

Group type: EXPERIMENTAL
Intervention: G‐CSF at 10 microg/kg body weight for 6 days in addition to standard care (aspirin, clopidogrel, ACE inhibitor, beta-blocking agents, statins)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 50
Study: 11929645

Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl estradiol/150 microg levonorgestrel (three cycles)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl estradiol/75 microg gestodene (three cycles)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both contraceptive treatments
Number of subjects: 12
Study: 9852409

Group type: EXPERIMENTAL
Intervention: Apheresis RBCs
Number of subjects: 21

Group type: COMPARATOR
Intervention: Manual RBCs
Number of subjects: 21
Study: 8572909

Group type: EXPERIMENTAL
Intervention: Anger condition
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Anxiety condition
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 48
Study: 2242519

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 183

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 183
Study: 28313

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg (Halcion)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 31429793

Group type: EXPERIMENTAL
Intervention: Nifurtimox (NFX/120HD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benznidazole (BZN/60CD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28075066

Group type: EXPERIMENTAL
Intervention: Alogliptin + Metformin FDC (12.5 mg + 500 mg BID)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5 mg BID)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg BID)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 647
Study: 26175027

Group type: EXPERIMENTAL
Intervention: TDEN vaccine (two formulations)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study: 23222078

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 39
Study: 21746728

Group type: EXPERIMENTAL
Intervention: Sensitivity to secondhand smoke exposure (SHSe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline SHSe reactions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of smoking susceptibility
Number of subjects: 0
Study: 19840752

Group type: COMPARATOR
Intervention: Intraoperative pedography (IP) used in 52 patients.
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intraoperative pedography (control group).
Number of subjects: 100
Study: 16424233

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid IL-6 concentrations at presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid inflammatory cytokines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid IFN-gamma concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral blood IFN-gamma ELISPOT responses to Mycobacterium tuberculosis Ags (ESAT-6, CFP-10, PPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cerebrospinal fluid inflammatory indices
Number of subjects: 0
Study: 14871958

Group type: EXPERIMENTAL
Intervention: Vaccination with HLA‐A2‐restricted hTERT I540 peptide presented with keyhole limpet hemocyanin by ex vivo generated autologous dendritic cells
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with hTERT peptide
Number of subjects: 7
Study: 11407800

Group type: EXPERIMENTAL
Intervention: 2 cm artificial limb-length discrepancy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 3 cm artificial limb-length discrepancy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 4 cm artificial limb-length discrepancy
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0 cm artificial limb-length discrepancy (control)
Number of subjects: 44
Study: 11185668

Group type: EXPERIMENTAL
Intervention: Pilocarpine (single oral doses ranging from 2.5 to 20 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (normal healthy volunteers)
Number of subjects: 42
Study: 8965040

Group type: EXPERIMENTAL
Intervention: Echotrace (graphic software system)
Number of subjects: 29
Study: 1495686

Group type: EXPERIMENTAL
Intervention: Secondary closure
Number of subjects: 33

Group type: COMPARATOR
Intervention: Secondary intention
Number of subjects: 33
Study: 6188892

Group type: EXPERIMENTAL
Intervention: Pirmenol (150 mg/30 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lidocaine (250 mg/30 min)
Number of subjects: 12
Study: 29251176

Group type: EXPERIMENTAL
Intervention: Immersion (egocentric perspective)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Distancing (observer perspective)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed by Beck Depression Inventory-II
Number of subjects: 6

Group type: COMPARATOR
Intervention: Distancing
Number of subjects: 6
Study: 29322594

Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/day)
Number of subjects: 30
Study: 26956726

Group type: EXPERIMENTAL
Intervention: Tailored interventions including outreach visits, a website with recommendations, tools for managing depression, and a continuous medical education course for general practitioners.
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group (standard care without tailored interventions).
Number of subjects: 900
Study: 25377015

Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheter (IPC) management
Number of subjects: 146

Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 146
Study: 22727733

Group type: EXPERIMENTAL
Intervention: sorafenib 400mg orally b.i.d. on a continuous basis
Number of subjects: 602

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 602
Study: 20797314

Group type: EXPERIMENTAL
Intervention: CYP1A2 gene polymorphisms (CYP1A2*1C, CYP1A2*1D, CYP1A2*1E, CYP1A2*1F)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 100
Study: 18240834

Group type: EXPERIMENTAL
Intervention: Patient vigilance system (passive sensor array and bedside unit connected to nurse call system)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient vigilance system
Number of subjects: 0
Study: 15856079

Group type: EXPERIMENTAL
Intervention: Sertraline or bupropion treatment for 5 weeks
Number of subjects: 13
Study: 11991878

Group type: EXPERIMENTAL
Intervention: Inhaled substance P
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled neurokinin A (Control)
Number of subjects: 12
Study: 9805723

Group type: EXPERIMENTAL
Intervention: New antenatal care programme
Number of subjects: 24000

Group type: COMPARATOR
Intervention: Traditional programme currently in use
Number of subjects: 24000
Study: 7701550

Group type: COMPARATOR
Intervention: Immuninehep-plus
Number of subjects: 53

Group type: COMPARATOR
Intervention: Immuninehep-minus
Number of subjects: 53

Group type: COMPARATOR
Intervention: Bebulin (control)
Number of subjects: 53
Study: 2482677

Group type: EXPERIMENTAL
Intervention: HES 6% (mean molecular weight = 40,000)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 10
Study: 30051418

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study: 28602783

Group type: EXPERIMENTAL
Intervention: Recommended pharmacotherapy
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Osteoporosis knowledge
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Fear of adverse effects
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Dislike of taking medicine
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Belief that medication would not help
Number of subjects: 790
Study: 25091720

Group type: EXPERIMENTAL
Intervention: Community-based relapse prevention program (CBRP)
Number of subjects: 71
Study: 22651242

Group type: EXPERIMENTAL
Intervention: Care provided by nurse specialists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care-as-usual by GPs (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse specialist involvement (from GPs' perspective)
Number of subjects: 0
Study: 21692759

Group type: EXPERIMENTAL
Intervention: Sled-mounted needle guide (sled group, n = 23)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasound without the sled (control group, n = 27)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sled group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 19635615

Group type: EXPERIMENTAL
Intervention: BZA (20 mg)/CE (0.625 or 0.45 mg)
Number of subjects: 3397

Group type: EXPERIMENTAL
Intervention: BZA/CE
Number of subjects: 3397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study: 16456441

Group type: EXPERIMENTAL
Intervention: Tracheostomy before day 8 postinjury
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tracheostomy after day 28 postinjury
Number of subjects: 60
Study: 15242359

Group type: EXPERIMENTAL
Intervention: Naftopidil (50-75 mg daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Eviprostat (six tablets daily)
Number of subjects: 49
Study: 11760371

Group type: COMPARATOR
Intervention: Interferon alfa 5 million units thrice weekly plus oral ribavirin 1,200 mg daily for 24 weeks (regimen A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Interferon alfa 5 million units thrice weekly plus oral ribavirin 1,200 mg daily for 24 weeks followed by interferon alfa 3 MU thrice weekly for another 24 weeks (regimen B)
Number of subjects: 36
Study: 9531230

Group type: EXPERIMENTAL
Intervention: Esterified estrogens 0.3 mg/d
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Esterified estrogens 0.625 mg/d
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Esterified estrogens 1.25 mg/d
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 8237801

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 159

Group type: COMPARATOR
Intervention: Celiprolol
Number of subjects: 159
Study: 3307421

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30324560

Group type: EXPERIMENTAL
Intervention: Chewable toothbrush (CT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual toothbrush (MT)
Number of subjects: 60
Study: 28600104

Group type: EXPERIMENTAL
Intervention: Polarization microscopy (PM) imaging at 5 hours after insemination
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Polarization microscopy (PM) imaging at 6 hours after insemination
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Polarization microscopy (PM) imaging at 4 hours after insemination
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Rescue intracytoplasmic sperm injection (ICSI)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Spindle visualization method
Number of subjects: 85
Study: 26196502

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg daily) plus Sofosbuvir (400 mg daily) for 12 weeks
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Daclatasvir (60 mg daily) plus Sofosbuvir (400 mg daily) for 8 weeks
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Daclatasvir plus Sofosbuvir across all genotypes
Number of subjects: 203
Study: 23521151

Group type: EXPERIMENTAL
Intervention: Weight-based nomogram alone (Group 1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Weight-based nomogram combined with suprasternal palpation (Group 2)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination of weight-based and suprasternal methods by personnel not specially trained (Group 3)
Number of subjects: 57
Study: 21417936

Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine (group A)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of 10 mL 2% lidocaine and 10 mL 0.5% bupivacaine (group B)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Pretreatment stent placement
Number of subjects: 125
Study: 19105585

Group type: EXPERIMENTAL
Intervention: Cilomilast 15 mg, twice daily for 24 weeks
Number of subjects: 2088

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2088